Abstract:A dopamine derivative, 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, known as salsolinol (SAL), has increasingly gained attention since its first detection in the urine of Parkinson's disease patients treated with levodopa, and has been proposed as a possible neurotoxic contributor to the disease. Yet, so far, the neurobiological role of SAL remains unclear. Thus, the main aims of our study were to compare the neurotoxic potential of SAL with MPP + (1-methyl-4-phenylpyridinium ion) in vitro, and to examine intestinal and metabolic alterations following intraperitoneal SAL administration in vivo. In vitro, SH-SY5Y neuroblastoma cell line was monitored following MPP + and SAL treatment. In vivo, Wistar rats were subjected to SAL administration by either osmotic intraperitoneal mini-pumps or a single intraperitoneal injection, and after two weeks, biochemical and morphological parameters were assessed. SH-SY5Y cells treated with MPP + (1000 μM) and SAL (50 μM) showed increase in cell viability and fluorescence intensity in comparison with the cells treated with MPP + alone. In vivo, we predominantly observed decreased collagen content in the submucosal layer, decreased neuronal density with comparable ganglionic area in the jejunal myenteric plexus, and increased glial S100 expression in both enteric plexuses, yet with no obvious signs of inflammation. Besides, glucose and triglycerides levels were lower after single SAL-treatment (200 mg/kg), and low- to high-density lipoprotein (LDL/HDL) ratio and aspartate to alanine aminotransferases (AST/ALT) ratio levels were higher after continuous SAL-treatment (200 mg/kg in total over 2 weeks). Low doses of SAL were non-toxic and exhibited pronounced neuroprotective properties against MPP + in SH-SY5Y cell line, which supports the use of SAL as a reference compound for in vitro studies. In vivo results give insight into our understanding of gastrointestinal remodeling following intraperitoneal SAL administration, and might represent morphological correlates of a microglial-related enteric neurodegeneration and dopaminergic dysregulation.

Salsolinol Damaged Neuroblastoma SH-SY5Y Cells Induce Proliferation of Human Monocyte THP-1 Cells Through the mTOR Pathway in a Co-culture System

Salsolinol Induces Parkinson's Disease Through Activating NLRP3-Dependent Pyroptosis and the Neuroprotective Effect of Acteoside

Sal Synthase Induced Cytotoxicity of PC12 Cells Through Production of the Dopamine Metabolites Salsolinol and N-methyl-salsolinol.

Endoplasmic Reticulum Stress And Nf-Kappa B Pathway In Salidroside Mediated Neuroprotection: Potential Of Salidroside In Neurodegenerative Diseases

Salsolinol Protects SH-SY5Y Cells Against MPP+ Damage and Increases Enteric S100-Immunoreactivity in Wistar Rats

Damage Of Neuroblastoma Cell Sh-Sy5y Mediated By Mpp+ Inhibits Proliferation Of T-Cell Leukemia Jurkat By Co-Culture System

Salvianolic Acid B Protects SH-SY5Y Neuroblastoma Cells from 1-Methyl-4-phenylpyridinium-induced Apoptosis.

Increased Vulnerability of Parkin Knock Down PC12 Cells to Hydrogen Peroxide Toxicity: the Role of Salsolinol and NM-salsolinol

Salidroside Protects SH‑SY5Y from Pathogenic Α‑synuclein by Promoting Cell Autophagy Via Mediation of Mtor/p70s6k Signaling.

Salvianolic acid B protects against MPP+-induced neuronal injury via repressing oxidative stress and restoring mitochondrial function

Butyrate Protects Against Salsolinol-Induced Toxicity in SH-SY5Y Cells: Implication for Parkinson’s Disease

Neuroprotective effect of salidroside against 6-OHDA-induced oxidative stress in PC12 cells

S-adenosyl Methionine Enhance the Toxicity of Salsolinol in Dopaminergic SH-SY5Y Cell

Salidroside improves cognitive function in Parkinson's disease via Braf-mediated mitogen‐activated protein kinase signaling pathway

Sulforaphane protects against rotenone-induced neurotoxicity in vivo : Involvement of the mTOR, Nrf2 and autophagy pathways

TRPC1 Protects Dopaminergic SH-SY5Y Cells from MPP+, Salsolinol, and N-methyl-(R)-salsolinol-induced Cytotoxicity.

Changes in salsolinol production and salsolinol synthase activity in Parkinson's disease model.

Acteoside Alleviates Salsolinol-Induced Parkinson's Disease by Inhibiting Ferroptosis Via Activating Nrf2/SLC7A11/GPX4 Pathway

Salsolinol as an RNA m6A methylation inducer mediates dopaminergic neuronal death by regulating YAP1 and autophagy

Insulin-like growth factor-1 protects human dopaminergic SH-SY5Y cells from salsolinol-induced toxicity.

Salidroside Promotes the Pathological Α-Synuclein Clearance Through Ubiquitin-Proteasome System in SH-SY5Y Cells